Want to see CORT full AI Analyst Report?
Top Page
Corcept Therapeutics
(NASDAQ:CORT)
Select Model
Select Model
Rating:78Outperform
Price Target:
$134.00
▲(8.44% Upside)
Action:Reiterated
Date:09/23/26
The score is driven primarily by strong financial quality (low leverage and solid cash generation) and a favorable technical uptrend, reinforced by a bullish earnings-call outlook with raised guidance and strong commercial momentum. The main offset is valuation risk from an exceptionally high P/E, which reduces the margin of safety.
Positive Factors
Lifyorli commercial adoption
Rapid patient starts, broad prescriber adoption, and coverage across more than 70% of lives indicate a strong launch foundation. These access and utilization advantages can support durable oncology revenue growth as physicians gain experience and treatment adoption expands.
Negative Factors
Recent profitability compression
The sharp decline in net margin indicates that strong gross product economics have not translated into equally durable bottom-line performance recently. If lower operating profitability persists, Corcept may have less earnings leverage from revenue growth and reduced capacity to convert commercial momentum into shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Lifyorli commercial adoption
Rapid patient starts, broad prescriber adoption, and coverage across more than 70% of lives indicate a strong launch foundation. These access and utilization advantages can support durable oncology revenue growth as physicians gain experience and treatment adoption expands.
Read all positive factors
Corcept Therapeutics Key Performance Indicators (KPIs)
Any
Research & Development Expense Breakdown
Allocation of R&D spending across programs and trial stages reveals how Corcept is prioritizing its pipeline—whether cash is focused on late‑stage clinical trials that could produce near‑term approvals and revenue, or on early discovery that points to longer‑term growth. Changes in the mix and absolute R&D spend also signal the company’s cash burn and financing needs, the surface area for regulatory and clinical risk, and how management balances short‑term commercial support with long‑term drug development.
Allocation of R&D spending across programs and trial stages reveals how Corcept is prioritizing its pipeline—whether cash is focused on late‑stage clinical trials that could produce near‑term approvals and revenue, or on early discovery that points to longer‑term growth. Changes in the mix and absolute R&D spend also signal the company’s cash burn and financing needs, the surface area for regulatory and clinical risk, and how management balances short‑term commercial support with long‑term drug development.
Data provided by:
The Fly
The FlyCorcept Therapeutics (CORT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.56B
Dividend YieldN/A
Average Volume (3M)1.43M
Price to Earnings (P/E)223.5
Beta (1Y)0.44
Revenue Growth16.02%
EPS Growth-59.24%
CountryUS
Employees730
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.52
Shares Outstanding108,098,400
10 Day Avg. Volume2,586,074
30 Day Avg. Volume1,425,513
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue12.03
Enterprise Value/Gross Profit12.24
Enterprise Value/Ebitda347.17
Forecast
1Y Price Target
$141.00Price Target Upside14.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)2.06
Revenue Forecast (FY)$1.11B
Corcept Therapeutics Business Overview & Revenue Model
Company Description
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsyc...
How the Company Makes Money
Corcept primarily makes money from net product revenue generated by sales of its marketed drug, Korlym (mifepristone), in the United States. Revenue is recognized from product shipments/sales to customers, net of estimated allowances such as produ...
Corcept Therapeutics Earnings Call Summary
Earnings Call Date:Jul 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call highlights robust commercial momentum and meaningful clinical and regulatory progress: strong Q2 financials (+32% revenue growth), a fast and well‑covered Lifyorli launch with survival data supporting uptake, record Korlym prescribing driven by shifting clinical awareness, and multiple near‑term trial readouts. Offsetting these positives are residual regulatory risk for relacorilant (prior CRL, PDUFA Dec 17, 2026), tolerability concerns and mixed statistical significance in early ALS results, and the usual clinical/regulatory execution risks across the pipeline. On balance, the positive financial performance, rapid oncology launch, and pipeline catalysts outweigh the noted risks.Positive Updates
Strong Revenue Growth
Total revenue for Q2 2026 was $256.0 million, a 32% increase year-over-year. Korlym + authorized generic revenue were $208.6 million and Lifyorli generated $47.6 million in its first quarter of availability.
Negative Updates
Earlier Complete Response Letter for Relacorilant
The FDA issued a CRL at the end of last year for relacorilant, reflecting prior regulatory concerns. Although the company resubmitted analyses and received acceptance, regulatory risk remains until the Dec 17, 2026 PDUFA decision.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Total revenue for Q2 2026 was $256.0 million, a 32% increase year-over-year. Korlym + authorized generic revenue were $208.6 million and Lifyorli generated $47.6 million in its first quarter of availability.
Read all positive updates
Company Guidance
Management raised 2026 revenue guidance to $1.1–$1.2 billion; reported Q2 revenue of $256 million (up 32% YoY) with Korlym and authorized generic revenue of $208.6 million and Lifyorli product revenue of $47.6 million in its first quarter, net income of $43 million (vs. $35M prior year), cash and investments of $545 million at June 30, and operating expenses flat to Q1; they forecast the Cushing’s syndrome business to reach at least $2 billion in annual revenue by the end of the decade (and, per the call, $3–$5 billion with relacorilant), see Lifyorli growing to more than $1 billion annually in the U.S., noted >1,300 patients have started Lifyorli with >1,000 unique prescribers and formal coverage for >70% of combined lives, and highlighted upcoming readouts (BELLA/STELLA/TRIDENT by end of next year, MONARCH and DAZZLE this year) including clinical signals such as ROSELLA’s 35% reduction in risk of death (HR 0.65, p=0.04) and DAZZLE’s 84% 1‑year mortality reduction (p=0.09) and 87% at year two (p<0.01).Corcept Therapeutics Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
92
Very Positive
Cash Flow
76
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 830.81M | 761.41M | 675.04M | 482.38M | 401.86M | 365.98M |
| Gross Profit | 816.73M | 748.43M | 664.16M | 475.89M | 396.47M | 360.70M |
| EBITDA | 28.79M | 68.35M | 162.83M | 125.60M | 117.45M | 127.95M |
| Net Income | 54.90M | 99.65M | 139.73M | 106.14M | 101.42M | 112.51M |
Balance Sheet | ||||||
| Total Assets | 888.70M | 836.65M | 840.55M | 621.52M | 583.43M | 423.76M |
| Cash, Cash Equivalents and Short-Term Investments | 308.20M | 372.15M | 383.33M | 368.22M | 431.67M | 223.53M |
| Total Debt | 9.42M | 6.11M | 6.94M | 151.00K | 1.14M | 526.00K |
| Total Liabilities | 182.93M | 188.85M | 160.96M | 114.81M | 81.59M | 47.95M |
| Stockholders Equity | 705.78M | 647.80M | 679.59M | 506.70M | 501.84M | 375.81M |
Cash Flow | ||||||
| Free Cash Flow | 106.92M | 141.78M | 195.90M | 126.90M | 119.91M | 167.42M |
| Operating Cash Flow | 109.70M | 142.00M | 198.07M | 127.04M | 120.32M | 167.89M |
| Investing Cash Flow | -21.90M | 69.76M | -177.60M | 90.91M | -114.33M | 136.13M |
| Financing Cash Flow | -78.91M | -220.37M | -28.35M | -148.72M | -17.28M | -302.59M |
Corcept Therapeutics Technical Analysis
Positive
123.57
Price Trends
113.00
Positive
95.67
Positive
69.92
Positive
Market Momentum
0.95
Positive
54.07
Neutral
50.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Positive. The current price of 123.57 is above the 20-day moving average (MA) of 114.16, above the 50-day MA of 113.00, and above the 200-day MA of 69.92, indicating a bullish trend. The MACD of 0.95 indicates Positive momentum. The RSI at 54.07 is Neutral, neither overbought nor oversold. The STOCH value of 50.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CORT.
Corcept Therapeutics Risk Analysis
Corcept Therapeutics disclosed 30 risk factors in its most recent earnings report. Corcept Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Corcept Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $5.91B | 70.83 | 13.65% | ― | 58.85% | 1646.61% | |
78 Outperform | $12.56B | 223.52 | 8.37% | ― | 16.02% | -59.24% | |
64 Neutral | $2.56B | 18.25 | 149.64% | ― | 2233.65% | ― | |
54 Neutral | $88.33M | -1.99 | -102.97% | ― | ― | ― | |
52 Neutral | $50.94M | -2.78 | -21.10% | ― | 489.78% | 45.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CORT
Corcept Therapeutics
116.23
26.38
29.36%
SCYX
SCYNEXIS
5.12
-1.19
-18.81%
KNSA
Kiniksa Pharmaceuticals
75.79
37.50
97.94%
LQDA
Liquidia Technologies
28.64
5.78
25.28%
CTOR
Citius Oncology
0.95
-0.92
-49.20%
NSRX
Nasus Pharma Ltd.
3.92
-3.13
-44.40%
Corcept Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Corcept Therapeutics Announces New Endocrinology Division President
Positive
Sep 23, 2026
On September 22, 2026, Corcept Therapeutics said Sean Maduck, president of its Endocrinology division, notified the board he would resign effective October 1, 2026, after a 14-year tenure in which he helped expand treatment for patients with Cushi...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Corcept Therapeutics Raises 2026 Revenue Outlook on Momentum
Positive
Jul 29, 2026
In the quarter ended June 30, 2026, Corcept Therapeutics reported revenue of $256.1 million, up 32 percent from the same period in 2025, with strong contributions from Korlym and its authorized generic, and $47.6 million from Lifyorli in its first...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.